Liver News and Research

RSS

Cholesterol efflux appears to be superior indicator of cardiovascular risk

Groundbreaking research from UT Southwestern Medical Center shows that cholesterol efflux capacity (cholesterol efflux), which measures HDL cholesterol function, appears to be a superior indicator of cardiovascular risk and a better target for therapeutic treatments than standard measurements of HDL. Current measurement methods reflect only the circulating levels of HDL and not the functional properties of this lipoprotein.

19 Nov 2014

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia.

18 Nov 2014

Common antimicrobial in household items causes liver fibrosis, cancer in mice

Triclosan is an antimicrobial commonly found in soaps, shampoos, toothpastes and many other household items. Despite its widespread use, researchers at University of California, San Diego School of Medicine report potentially serious consequences of long-term exposure to the chemical.

18 Nov 2014

ZS Pharma reports positive ZS-9 Phase 3 clinical trial for treatment of hyperkalemia

ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today presented detailed results from HARMONIZE (ZS004) at the late-breaking Clinical Science Special Reports Session of the American Heart Association Scientific Sessions.

18 Nov 2014

Research finding points to potential new treatment for metabolic disorders

Researchers at the University of Michigan have discovered how a previously unknown hormone serves as a messenger from fat cells to the liver and are investigating the potential of developing a new treatment for metabolic disorders.

17 Nov 2014

Chemical compound in coffee may help prevent damaging effects of obesity

Researchers at the University of Georgia have discovered that a chemical compound commonly found in coffee may help prevent some of the damaging effects of obesity.

17 Nov 2014

UNC researchers develop new approach to block KRAS oncogene

Researchers from the UNC School of Medicine and colleagues at The University of Texas MD Anderson Cancer Center have developed a new approach to block the KRAS oncogene, one of the most frequently mutated genes in human cancer.

14 Nov 2014

Study: Critically ill newborns may be exposed to DEHP chemicals in medical products

Hospitalized premature infants are exposed to unsafe levels of a chemical found in numerous medical products used to treat them, raising questions about whether critically ill newborns may be adversely affected by equipment designed to help save their lives.

14 Nov 2014

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

AstraZeneca and Isis Pharmaceuticals Inc. today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides.

14 Nov 2014

Montefiore Medical Center receives $3.5M grant to advance treatment for hepatitis C

Montefiore Medical Center received a $3.5 million grant as part of the $10 million Health Care Innovation Award from the Center for Medicare & Medicaid Services to identify, diagnose and treat people with hepatitis C (HCV).

13 Nov 2014

New treatment regimen for hepatitis C in transplant patients produces promising results

A new treatment regimen for hepatitis C, the most common cause of liver cancer and transplantation, has produced results that will transform treatment protocols for transplant patients, according to research published online today in the New England Journal of Medicine.

12 Nov 2014

Study examines overall survival of patients with chronic HCV infection, cirrhosis

Patients with chronic hepatitis C virus infection and advanced fibrosis or cirrhosis who attained sustained virological response (SVR) had survival comparable with that of the general population, whereas patients who did not attain SVR had reduced survival, according to a study in the November 12 issue of JAMA.

12 Nov 2014

New findings could help develop therapeutic options for glycogen storage disease

Glycogen storage disorders, which affect the body's ability to process sugar and store energy, are rare metabolic conditions that frequently manifest in the first years of life. Often accompanied by liver and muscle disease, this inability to process and store glucose can have many different causes, and can be difficult to diagnose.

11 Nov 2014

FDA accepts Amgen's evolocumab BLA for review

Amgen today announced that the U.S. Food and Drug Administration has accepted for review Amgen's Biologics License Application (BLA) for evolocumab for the treatment of high cholesterol.

11 Nov 2014

Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

All patients with hepatitis C who receive a liver transplant will eventually infect their new livers. These transplanted organs then require anti-viral treatment before they become severely damaged. But traditional post-transplant hepatitis C therapy can take up to a year, is potentially toxic and can lead to organ rejection.

11 Nov 2014

Resonance Health launches new diagnostic imaging solution for patients with fatty liver disease

ASX listed Resonance Health officially launched an innovative new diagnostic imaging solution for liver patients worldwide at the American Association for the Study of Liver Diseases annual conference in Boston this week.

10 Nov 2014

Obeticholic acid improves liver health in people with nonalcoholic steatohepatitis

An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the National Institutes of Health. The FLINT study found that people with nonalcoholic steatohepatitis (NASH) who took obeticholic acid (OCA) had improved liver health during that period, including decreased inflammation and fat in the liver and decreased body weight versus people receiving a placebo. OCA was also associated with increases in itching and total cholesterol.

7 Nov 2014

Liver News and Research

Cholesterol efflux appears to be superior indicator of cardiovascular risk

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

Common antimicrobial in household items causes liver fibrosis, cancer in mice

ZS Pharma reports positive ZS-9 Phase 3 clinical trial for treatment of hyperkalemia

Research finding points to potential new treatment for metabolic disorders

Chemical compound in coffee may help prevent damaging effects of obesity

UNC researchers develop new approach to block KRAS oncogene

Study: Critically ill newborns may be exposed to DEHP chemicals in medical products

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

Montefiore Medical Center receives $3.5M grant to advance treatment for hepatitis C

New treatment regimen for hepatitis C in transplant patients produces promising results

Study examines overall survival of patients with chronic HCV infection, cirrhosis

New findings could help develop therapeutic options for glycogen storage disease

FDA accepts Amgen's evolocumab BLA for review

Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

Resonance Health launches new diagnostic imaging solution for patients with fatty liver disease

Obeticholic acid improves liver health in people with nonalcoholic steatohepatitis

D-LIVER project aims to help patients with chronic liver disease

IU School of Medicine researchers identify new protein that can control diabetes

Common drug could become the future standard of care for HE patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News